Analiza uspeha lečenja obolelih od šećerne bolesti tip 2 u Specijalnoj bolnici “Merkur”
Sažetak
Cilj rada. Analiza uspeha lečenja obolelih od dijabetesa tipa 2 u Specijalnoj bolnici Merkur u toku destetodnevnog boravka u okviru programa Edukacije i prevencije komplikacija.
Metode. Istraživanje je obuhvatilo 126 pacijenata obolilih od dijabetesa koji su bili na desetodnevnom lečenju u periodu od januara do maja 2012. godine. Parametri na osnovu kojih su pacijenti podeljeni u grupu A sa poboljšanjem i grupu B bez poboljšanja su : aktuelne vrednosti gikemija u početnom i završnom profilu, srednje vrednosti glikemije u profilu i glikemijske varijabilnosti. Statistička obrada podataka vršena je studentovim t testom, Mann Whitney U testom , h² testom.
Rezultati: Analizom početnog profila registruje se statističko visoko značajne razlike vrednosti glikemija stim što su te vrednosti veće u grupi pacijenata kod kojih je registrovan pozitivan efekat lečenja . Verovatnoće iznose: p< 0,05(7h) p<0,001(10h) , p< 0,001(12h), p<0,05 (14h), p<0,05 (18h,) p< 0,05 (21h), p< 0,05 (24h), p< 0,001 (03h) . Dobijena je značajna statistička razlika između srednjih vrednosti glikemije u prvom profilu (MBG1 P<0,001) i prosečnog odstupanja od srednje vrednosti glikemije u prvom profilu (MAGE1 P<0,05.) Analizom glikemija u profilu na kraju lečenja mogu se uočiti niže prosečne vrednosti glikemija i u grupi A ali bez statistički značajne razlike. Statističku značajnost ima sniženje glikemijske varijabilnosti u drugom profilu (MAGE 2 p< 0,05) . Statistička značajnost je utvrđena i u razlici srednjih vrednosti oba profila (RMBG ) i razlici (RMAGE) oba profila u grupi A i B.
Zaključak. Bolji efekat se postiže kod pacijenata sa početnom lošijom glikoregulacijom tj. većim vrednostima MBG i MAGE.
Ključne reči: diabetes, glikoregulacija, glikemijska varijabilnost
Reference
Lalić N, Pantelinac P, Milovanović V. Terapija dijabetesa U: Nacionalni vodič kliničke prakse Diabetes mellitus, Beograd, 2002; 11-38.
Monnier L, Colette C, Owens DR. Glycaemic variability: the third component of the dysglycaemia in diabetes: is it important? How to measure it? J Diabetes Sci Technol 2008; 2:1094-1100.
Owens D, Tajima N, Tuomilehto J. A for the International Prandial Glucose Regulation (PGR) Study Group: Postprandial Glucose Regulation and Diabetic Complications. Arch Intern Med 164:2090-2095, 2004.
Wang Z, Li L, Zheng F, Jia C, Ruan Y, Li H. Correlation between the amplitude of glucose excursion and the oxidative/antioxidative system in subjects with different types of glucose regulation. Biomed Environ Sci. 2011;24(1):68-73
Zheng F, Wang Z, Li H, Jia CF, Zhang N, Yuan H. Correlation between the amplitude of glucose excursion and plasma 8-iso prostaglandin F2 alpha level in subjects with different types of glucose regulation. Zhonghua Yi Xue Za Zhi. 2009;89(10):651-4
American Diabetes Association Clinical Practice Recommendations: Executive Summary: Standards of Medical Care in Diabetes 2010 Diabetes Care 2010;33, suppl.1: S45
International Diabetes Federation guidelines: Global guidelines for type 2 diabetes 2005. Available at: http://www.idf.org
American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1):S11-61
Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25:1439-1443. 43
Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care29:1486–1490, 2006
Buckingham B, Black J, Wilson DM: Continuous glucose monitoring.Current Opin Endocrinol Diabetes 12:273–279, 2005
Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011; 34:855–85
Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551–565
DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397-405
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358; 2545-2559
Živković N, Živojinović D . Hipertenzija i ishemijska bolest srca kod djabetičara tip 2 na insulinskoj terapiji iz programa edukacije u centralnom delu Srbije. Congress of Serbian society of hypertension with international participation, Beograd, Serbia, 26-28.febr.2010;
Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of longterm complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45:1289-1298
Monnier L, Colette C, Owens D. Postprandial and basal Glucose in Type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther. 2011; 13 (Suppl) 1:s25-32
Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an oldparadigm. Oxford Jurnals 2000 vol47 Cardiovasc Res 47:475–488.
L. Nalysnyk M, Hernandez-Medina, G. Krishnarajah. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes, Obesity and Metabolism Volume 12, Issue 4, pages 288–298, April 2010
Skyler J, Bergenstal R, Bonow R, Buse J, Deedwania P, Gale E, Howard B, Kirkman M, Kosiborod M, Reaven P, Sherwin R; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-92
Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009 32:381–386
Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152:27-38
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765-1772.
Gerstein H, Miller M, Byington R, et al.. Action to Control Cardiovascular Risk in Diabetes Study Group, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59
Milovanović B, Karamarković D,Živojinović D, Babić M. Edukativni program u Vnjačkoj banji Preliminarni rezultati 6. kongres o šećernoj bolesti sa međunarodnim učešćem 2009.